Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

A dual biomarker in non-small cell lung cancer that predicts Li Fraumeni syndrome : Lung cancer and Li Fraumeni.

Familial cancer - 1 Nov 2024

Sorscher Steven

Abstract excerpt

Non-small cell lung cancer is the most common cause of cancer death globally. When apparent incidental pathogenic germline variants (PGVs) are uncovered with routine next generation sequencing (NGS) of NSCLCs, germline testing (GT) is recommended to confirm that PGV. Because it is far more common that an uncovered tumor TP53 variant is related to a somatic event than an incidental PGV, however, GT for Li Fraumeni...

Topics

Humans
Li-Fraumeni Syndrome
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Tumor Suppressor Protein p53
Germ-Line Mutation
Biomarkers, Tumor
ErbB Receptors
Genetic Predisposition to Disease
Genetic Testing
High-Throughput Nucleotide Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39235550
DOI: 10.1007/s10689-024-00418-8

Genes

EGFR
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A dual biomarker in non-small cell lung cancer that predicts Li Fraumeni syndrome : Lung cancer and Li Fraumeni.PMID 39235550Read ↗

Clinical characteristics and management of Li-Fraumeni syndrome-associated lung cancer.Semantic proximity Read ↗

The Clinical and Molecular Profile of Lung Cancer Patients Harboring the TP53 R337H Germline Variant in a Brazilian Cancer Center: The Possible Mechanism of Carcinogenesis.Semantic proximity Read ↗

Characterizing Lung Cancer in Li-Fraumeni Syndrome.Semantic proximity Read ↗

Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.Semantic proximity Read ↗

High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome.Semantic proximity Read ↗

The role of germline mutations in non-small cell lung cancer: A systematic review of emerging genetic drivers and clinical implications.Semantic proximity Read ↗

EGFR-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline EGFR T790M Testing.Semantic proximity Read ↗

Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.Semantic proximity Read ↗

Synchronous Lung Adenocarcinomas With Distinct EGFR Mutations In A Patient With Li-Fraumeni SyndromeSemantic proximity Read ↗

Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.Semantic proximity Read ↗

Prevalence and Clinical Implications of Somatic and Germline EGFR Mutations in Patients with Non-Small Cell Lung CancerSemantic proximity Read ↗

Li Fraumeni syndrome in the UK: clinical characteristics and outcomes of TP53 carriersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.